Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid

Pharmaceutical Research

Volumn 23, Issue 8, 2006, Pages 1729-1735

  Okamura, Noboru ^a,b   Ohnishi, Shuichi ^a   Shimaoka, Hiroyuki ^a   Norikura, Ryo ^a   Hasegawa, Hiroshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carnitine homeostasis; Carnitine transporter; LLC PK1 cells; Pivalic acid; Valproic acid

Indexed keywords

ACYLCARNITINE; CARNITINE; CARNITINE DERIVATIVE; COTRANSPORTER; LEVACECARNINE; PIVALIC ACID; PIVALOYLCARNITINE; PRODRUG; SODIUM ION; SODIUM ION CARNITINE COTRANSPORTER; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROYLCARNITINE;

ANIMAL CELL; ARTICLE; BLOOD LEVEL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EXCRETION; HOMEOSTASIS; KIDNEY TUBULE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE LEVEL; URINARY EXCRETION;

ACETYLCARNITINE; ALGORITHMS; AMINO ACID TRANSPORT SYSTEMS, BASIC; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CARNITINE; CARRIER PROTEINS; ENZYME INHIBITORS; LLC-PK1 CELLS; PENTANOIC ACIDS; SWINE; VALPROIC ACID;

EID: 33746926424     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9002-9     Document Type: Article

References (32)

1. L. L. Bieber. Carnitine. Ann. Rev. Biochem. 57:261-283 (1988).
2. C. J. Rebouche and D. L. Mack. Sodium gradient-stimulated transport of L-carnitine into brush border membrane vesicles: kinetics, specificity, and regulation by dietary carnitine. Arch. Biochem. Biophys. 235:393-402 (1984).
3. B. Stieger, B. O'Neill, and S. Krähenbühl. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem. J. 309:643-647 (1995).
4. A. Marzo, A. E. Martelli, A. Mancinelli, G. Cardace, C. Corbelletta, E. Bassani, and M. Solbiati. Protein binding of L-carnitine family components. Eur. J. Drug Metab. Pharmacokinet. 3:364-368 (1991).
5. I. Tamai, R. Ohashi, J. Nezu, H. Yabuuchi, A. Oku, M. Shimane, Y. Sai, and A. Tsuji. Molecular and functional identification of sodium ion-dependent, high affinity human catnitine transporter OCTN2. J. Biol. Chem. 273:20378-20382 (1998).
6. X. Wu, P. D. Prasad, F. H. Leibach, and V. Ganapathy. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem. Biophys. Res. Commun. 246:589-595 (1998).
7. J. Nezu, I. Tamai, A. Oku, R. Ohashi, H. Yabuuchi, N. Hashimoto, H. Nikaido, Y. Sai, A. Koizumi, Y. Shoji, G. Takada, T. Matsuishi, M. Yoshino, H. Kato, T. Ohura, G. Tsujimoto, J. Hayakawa, M. Shimane, and A. Tsuji. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat. Genet. 21:91-94 (1999).
8. Y. Wang, J. Ye, V. Ganapathy, and N. Longo. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc. Natl. Acad. Sci. USA 96:2356-2360 (1999).
9. C. J. Rebouche. Carnitine metabolism and its regulation in microorganisms and mammals. Annu. Rev. Nutr. 18:39-61 (1998).
10. A. Marzo, E. Arrigoni Martelli, R. Urso, M. Rocchetti, V. Rizza, and J. G. Kelly. Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers. Eur. J. Clin. Pharmacol. 37:59-63 (1989).
11. A. Mancinelli, A. Longo, K. Shanahan, and A. M. Evans. Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 274:1122-1128 (1995).
12. +-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. 291:778-784 (1999).
13. E. P. Brass, M. D. Mayer, D. J. Mulford, T. K. Stickler, and C. L. Hoppel. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin. Pharmacol. Ther. 73:338-347 (2003).
14. E. Holme, J. Greter, C. E. Jacobson, S. Lindstedt, I. Nordin, B. Kristiansson, and U. Jodal. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 2:469-473 (1989).
15. B. Melegh, J. Kerner, and L. L. Bieber. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem. Pharmacol. 36:3405-3409 (1987).
16. K. Shimizu, A. Saito, J. Shimada, M. Ohmichi, Y. Hiraga, T. Inamatsu, K. Shimada, M. Tanimura, Y. Fujita, T. Nishikawa, T. Oguma, and S. Yamamoto. Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrob. Agents Chemother. 37:1043-1049 (1993).
17. T. Kanazu and T. Yamaguchi. Comparison of in vitro carnitine and glycine conjugation with branched-side chain and cyclic side chain carboxylic acids in rats. Drug Metab. Dispos. 25:149-153 (1997).
18. K. Mizojiri, S. Futaguchi, R. Norikura, Y. Katsuyama, T. Nagasaki, T. Yoshimori, and N. Nakanishi. Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs. Antimicrob. Agents Chemother. 39:1445-1453 (1995).
19. K. Totsuka, K. Shimizu, M. Konishi, and S. Yamamoto. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob. Agents Chemother. 36:757-761 (1992).
20. D. S. Millington, T. P. Bohan, C. R. Roe, A. L. Yergey, and D. J. Liberato. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin. Chim. Acta 145:69-76 (1985).
21. Y. Ohtani, F. Endo, and I. Matsuda. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J. Pediatr. 101:782-785 (1982).
22. J. P. Van Wouwe. Carnitine deficiency during valproic acid treatment. Int. J. Vitam. Nutr. Res. 65:211-214 (1995).
23. 1. Biochem. J. 277:199-203 (1985).
24. 1. Am. J. Physiol. 262:C59-C66 (1992).
25. 1 cells. Am. J. Physiol. 281:F273-F279 (2001).
26. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
27. B. Melegh, J. Kerner, G. Kispal, G. Acsadi, and M. Dani. Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children: decreased urinary excretion. Acta Pediatr. Hung. 28:137-142 (1987).
28. B. Melegh, J. Kerner, V. Jaszai, and L. L. Bieber. Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. Biochem. Med. Metab. Biol. 43:30-38 (1990).
29. I. Tein, S. DiMauro, Z. W. Xie, and D. C. De Vivo. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts. An in vitro model for the pathogenesis of valproic acid-associated carnitine deficiency. Pediatr. Res. 34:281-287 (1993).
30. P. Molstad, T. Bohmer, and K. Eiklid. Specificity and characteristics of the carnitine transport in human heart cells (CCL 27) in culture. Biochim. Biophys. Acta 471:296-304 (1977).
31. J. Li, D. L. Norwood, L. F. Mao, and H. Schulz. Mitochondrial metabolism of valproic acid. Biochemistry 30:388-394 (1991).
32. T. Sugimoto, H. Muro, M. Woo, N. Nishida, and K. Murakami. Valproate metabolites in high-dose valproate plus phenytoin therapy. Epilepsia 12:1200-1203 (1996).